The Interaction of β2 Glycoprotein-I and Heparin and Its Effect on β2 Glycoprotein-I Antiphospholipid Antibody Cofactor Function in Plasma

T McNally; S E Cotterell; I J Mackie; D A Isenberg; S J Machin

doi:10.1055/s-0038-1648918

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1994; 72(04): 578-581
DOI: 10.1055/s-0038-1648918

Original Article

Schattauer GmbH Stuttgart

The Interaction of β₂ Glycoprotein-I and Heparin and Its Effect on β₂ Glycoprotein-I Antiphospholipid Antibody Cofactor Function in Plasma

T McNally

¹The Department of Haematology, Department of Medicine, University College London Medical School, London, UK

,

S E Cotterell

¹The Department of Haematology, Department of Medicine, University College London Medical School, London, UK

,

I J Mackie

¹The Department of Haematology, Department of Medicine, University College London Medical School, London, UK

,

D A Isenberg

²Bloomsbury Rheumatology Unit, Department of Medicine, University College London Medical School, London, UK

,

S J Machin

¹The Department of Haematology, Department of Medicine, University College London Medical School, London, UK

› Author Affiliations

Abstract

PDF Download

Summary

β₂ glycoprotein-I (β₂GPI), a cofactor for antiphospholipid antibody (aPA) binding, binds to many anionic macromolecules including heparin. The nature of this interaction with heparin is not well understood and its effect on the purported biological functions of β₂GPI is unknown.

We have examined the interactions of dermatan sulphate (DS) and different pharmaceutical preparations of heparin with β₂GPI by crossed immunoelectrophoresis (CIE) and investigated the effect of these agents on plasma levels of p2GPI antigen (β₂GPI: Ag) by a standardised enzyme linked immunosorbent assay (ELISA). P2GPI aPA cofactor activity (β₂GPI:Cof) was also measured using a modified solid phase an-ti-phosphatidylserine (aPS) ELISA. CIE results confirmed a heparin-β₂GPI interaction with unfractionated (UF) heparin. β₂GPI:Ag levels were unaffected by any of the preparations investigated. There were no significant differences in β₂GPI:Cof activities of the samples containing LMW heparins or DS but levels of β₂GPI:Cof were increased in samples containing UF sodium and calcium heparin preparations (0.5 IU/ml Monoparin, p <0.05, and 10 IU/ml Liquemin and Calcipa-rine, p <0.05).

PDF (318 kb)

References

References
1 Kroll J, Larsen JK, Loft H, Ezban M, Wallewick K, Faber M. DNA binding proteins in Yoshida asites tumor fluid. Biochim Biophys Acta 1976; 434: 490-501
2 Polz E, Kostner GM. The binding of β₂ glycoprotein-I to human serum lipoproteins: distribution among density fractions. FEBS Letters 1979; 102: 183-186
3 Schousboe I. Binding of β₂ glycoprotein-I to platelets: effect on adenylate cyclase activity. Thromb Res 1980; 19: 225-237
4 Schousboe I. Characterization of the interaction between β₂ glycoprotein-I and mitochondria, platelets, liposomes and bile acids. Int J Biochem 1983; 15: 1393-1401
5 Polz E, Wurm H, Kostner GM. Investigations on β₂ glycoprotein-I in the rat: isolation from serum and demonstration in lipoprotein density fractions. Int J Biochem 1980; 11: 265-270
6 Schousboe I. β₂ glycoprotein-I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66: 1086-1091
7 Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaal RFA. Prothrombinase activity of human platelets is inhibited by β₂ glyco-protein-I. Biochim Biophys Acta 1986; 884: 142-149
8 Nimpf J, Wurm H, Kostner GM. Interaction of β₂ glycoprotein-I with human blood platelets: Influence upon ADP induced aggregation. Thromb Haemost 1985; 54: 397-401
9 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets HM, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) are directed not to a cardiolipin but to a plasma protein co-factor. Lancet 1990; 335: 1544-1547
10 McNeil HP, Simpson RJ, Chesterman CN, Krillis SA. Antiphospholipid antibodies are directed a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂ glycoprotein-I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
11 Bowie WEJ, Thompson JH, Pascuzzi CA, Owen GA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Clin Lab Med 1963; 62: 416-430
12 Nilsson IM, Asted B, Hedner U, Berezin D. Intrauterine death and circulating anticoagulant, „antithromboplastin‟. Acta Med scand 1975; 197: 153-175
13 Greaves M, Preston FE. Clinical and laboratory aspects of thrombophilia. In: Recent Advances in Blood Coagulation 5 1991. Churchill Livingstone; 119-140
14 Wagenknecht DR, McIntyre J. Interaction of heparin with β₂ glycoprotein-I and antiphospholipid antibodies in vitro. Throm Res 1992; 68: 495-500
15 McNally T, Mackie IJ, Isenberg DA, Machin SJ. Immunoelectrophoresis and ELISA techniques for assay of plasma β₂ glycoprotein-I and the influence of plasma lipids. Thromb Res 1993; 72: 275-286
16 Viard JP, Amoura Z, Bach JF. Association of anti-pβ₂ glycoprotein-I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. The American Journal of Medicine 1992; 93: 181-186
17 Laurell CB. Antigen-antibody crossed electrophoresis. Analytical Biochemistry 1965; 10: 358-361
18 Hirsh J. Mechanism of action and monitoring of anticoagulants. Seminars in Thrombosis and Haemostasis 1986; 12: 1-11
19 Ireland H, Rylance PB, Kesteven P. Heparin as an anticoagulant during ex-tracorporeal circulation. In: Heparin: Chemical and Biological Properties, Clinical Applications Lane DA, Lindahl U. (eds) Edward Arnold; 1989: 549-574
20 Hunt JE, Simpson RJ, Krilis SA. Identification of a region of β₂ glyco-protein-I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 1993; 90: 2141-2145
21 Wagenknecht DR, McIntyre JA. Changes in β₂ glycoprotein-I antigenicity induced by phospholipid binding. Thromb Haemost 1993; 69: 361-365